Teacher Retirement System of Texas Grows Stake in Henry Schein, Inc. $HSIC

Teacher Retirement System of Texas increased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 21.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,594 shares of the company’s stock after buying an additional 9,348 shares during the period. Teacher Retirement System of Texas’ holdings in Henry Schein were worth $3,491,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Dilation Capital Management LP purchased a new stake in shares of Henry Schein in the third quarter worth approximately $5,105,000. Rakuten Investment Management Inc. bought a new stake in shares of Henry Schein in the third quarter valued at about $713,000. Lee Danner & Bass Inc. raised its holdings in shares of Henry Schein by 1.8% in the 3rd quarter. Lee Danner & Bass Inc. now owns 53,300 shares of the company’s stock valued at $3,538,000 after purchasing an additional 965 shares in the last quarter. Stenger Family Office LLC increased its holdings in shares of Henry Schein by 9.6% in the 3rd quarter. Stenger Family Office LLC now owns 23,044 shares of the company’s stock valued at $1,529,000 after acquiring an additional 2,020 shares during the period. Finally, Ritholtz Wealth Management raised its holdings in Henry Schein by 62.6% in the third quarter. Ritholtz Wealth Management now owns 8,812 shares of the company’s stock worth $585,000 after purchasing an additional 3,394 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on HSIC. Morgan Stanley increased their price target on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Barclays started coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Wells Fargo & Company raised their price target on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. boosted their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $76.42.

Henry Schein Trading Down 2.3%

HSIC opened at $75.08 on Thursday. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The business has a fifty day simple moving average of $76.18 and a 200-day simple moving average of $70.73. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The firm has a market cap of $8.84 billion, a P/E ratio of 23.76, a P/E/G ratio of 2.29 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The firm had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, equities analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.